{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:48:16Z","timestamp":1790365696423,"version":"4.1.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T00:00:00Z","timestamp":1613088000000},"content-version":"am","delay-in-days":408,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"ABBVIE"},{"name":"BIOTEST"},{"DOI":"10.13039\/100006436","name":"CELGENE","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"crossref"}]},{"name":"ROCHE-CHUGAI"},{"DOI":"10.13039\/100005564","name":"GILEAD","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100011096","name":"JAZZ PHARMACEUTICALS","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"crossref"}]},{"name":"KEOCYT"},{"name":"MACOPHARMA"},{"name":"MALLINCKRODT THERAKOS"},{"name":"MSD FRANCE"},{"DOI":"10.13039\/100004336","name":"NOVARTIS","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.bulcan.2019.07.011","type":"journal-article","created":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T06:58:03Z","timestamp":1569999483000},"page":"S72-S84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"S","title":["Greffe de cellules souches h\u00e9matopo\u00ef\u00e9tiques haplo-identiques avec cyclophosphamide en post-greffe\u00a0: comment choisir le meilleur donneur en 2019\u00a0? Recommandations de la Soci\u00e9t\u00e9 francophone de greffe de m\u0153lle et de th\u00e9rapie cellulaire (SFGM-TC)"],"prefix":"10.1016","volume":"107","author":[{"given":"Val\u00e9rie","family":"Dubois","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kahina","family":"Amokrane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Beguin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Chevallier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Delbos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raynier","family":"Devillier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Giannoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwendaline","family":"Guidicelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mhamed","family":"Harif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Loiseau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul-Olivier","family":"Rouzaire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Varlet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11S","key":"10.1016\/j.bulcan.2019.07.011_bib0325","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1016\/j.bulcan.2016.09.006","article-title":"How we harmonize HSCT clinical practices among the SFGM-TC centers","volume":"103","author":"Tipton","year":"2016","journal-title":"Bull Cancer (Paris)"},{"issue":"4","key":"10.1016\/j.bulcan.2019.07.011_bib0330","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.patbio.2014.05.004","article-title":"Allogeneic stem cell transplantation from an HLA-haploidentical related donor: SFGM-TC recommendations (Part 1)","volume":"62","author":"Blaise","year":"2014","journal-title":"Pathol Biol (Paris)"},{"issue":"4","key":"10.1016\/j.bulcan.2019.07.011_bib0335","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.patbio.2014.05.002","article-title":"Allogeneic stem cell transplantation from an HLA-haploidentical related donor: SFGM-TC recommendations (part 2)","volume":"62","author":"Nguyen","year":"2014","journal-title":"Pathol Biol (Paris)"},{"issue":"11S","key":"10.1016\/j.bulcan.2019.07.011_bib0340","doi-asserted-by":"crossref","first-page":"S229","DOI":"10.1016\/j.bulcan.2016.09.007","article-title":"Haploidentical hematopoietic stem cell transplantation: guidelines from the francophone society of marrow transplantation and cellular therapy (SFGM-TC)","volume":"103","author":"Nguyen","year":"2016","journal-title":"Bull Cancer (Paris)"},{"issue":"8","key":"10.1016\/j.bulcan.2019.07.011_bib0345","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.bbmt.2015.05.001","article-title":"Complement-binding donor-specific anti-HLA antibodies and risk of primary graft failure in hematopoietic stem cell transplantation","volume":"21","author":"Ciurea","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.bulcan.2019.07.011_bib0350","doi-asserted-by":"crossref","first-page":"2880","DOI":"10.1016\/j.transproceed.2016.07.050","article-title":"Desensitization protocol in recipients of deceased kidney donor with donor-specific antibody-low titers","volume":"48","author":"Kanter Berga","year":"2016","journal-title":"Transplant Proc"},{"key":"10.1016\/j.bulcan.2019.07.011_bib0355","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13045-015-0182-9","article-title":"Donor-specific anti-human leukocyte antigen antibodies were associated with primary graft failure after unmanipulated haploidentical blood and marrow transplantation: a prospective study with randomly assigned training and validation sets","volume":"8","author":"Chang","year":"2015","journal-title":"J Hematol Oncol"},{"issue":"8","key":"10.1016\/j.bulcan.2019.07.011_bib0360","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1097\/TP.0b013e3181b9d710","article-title":"High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation","volume":"88","author":"Ciurea","year":"2009","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.bulcan.2019.07.011_bib0365","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/bmt.2011.131","article-title":"Risk and prevention of graft failure in patients with preexisting donor-specific HLA antibodies undergoing unmanipulated haploidentical SCT","volume":"47","author":"Yoshihara","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.bulcan.2019.07.011_bib0370","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41409-017-0062-8","article-title":"The European Society for Blood and Marrow Transplantation (EBMT) consensus guidelines for the detection and treatment of Donor-Specific Anti-HLA Antibodies (DSA) in haploidentical hematopoietic cell transplantation","volume":"53","author":"Ciurea","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.bulcan.2019.07.011_bib0375","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1016\/j.bbmt.2014.06.024","article-title":"Anti-HLA antibodies other than against HLA-A, -B, -DRB1\u00a0adversely affect engraftment and nonrelapse mortality in HLA-mismatched single cord blood transplantation: possible implications of unrecognized donor-specific antibodies","volume":"20","author":"Yamamoto","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.bulcan.2019.07.011_bib0380","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/bmt.2017.10","article-title":"Effective desensitization of donor-specific HLA antibodies using platelet transfusion bearing targeted HLA in a case of HLA-mismatched allogeneic stem cell transplantation","volume":"52","author":"Yamashita","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bulcan.2019.07.011_bib0385","doi-asserted-by":"crossref","first-page":"4025073","DOI":"10.1155\/2016\/4025073","article-title":"Donor Specific Anti-HLA Antibody and risk of graft failure in haploidentical stem cell transplantation","volume":"2016","author":"Kongtim","year":"2016","journal-title":"Adv Hematol"},{"issue":"3","key":"10.1016\/j.bulcan.2019.07.011_bib0390","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.transproceed.2015.11.027","article-title":"Progress in desensitization of the highly HLA sensitized patient","volume":"48","author":"Jordan","year":"2016","journal-title":"Transplant Proc"},{"issue":"3","key":"10.1016\/j.bulcan.2019.07.011_bib0395","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/TP.0000000000000064","article-title":"Benefits of rituximab combined with intravenous immunoglobulin for desensitization in kidney transplant recipients","volume":"98","author":"Vo","year":"2014","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.bulcan.2019.07.011_bib0400","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.bbmt.2009.11.011","article-title":"Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome","volume":"16","author":"Kasamon","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.bulcan.2019.07.011_bib0405","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.bbmt.2018.01.013","article-title":"Selecting the best donor for haploidentical transplant: impact of HLA. Killer cell immunoglobulin-like receptor genotyping, and other clinical variables","volume":"24","author":"Solomon","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.bulcan.2019.07.011_bib0410","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1182\/bloodadvances.2017014829","article-title":"Effect of donor characteristics on haploidentical transplantation with posttransplantation cyclophosphamide","volume":"2","author":"McCurdy","year":"2018","journal-title":"Blood Adv"},{"issue":"6","key":"10.1016\/j.bulcan.2019.07.011_bib0415","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/j.bbmt.2017.09.005","article-title":"Haploidentical transplantation for older patients with acute myeloid leukemia and myelodysplastic syndrome","volume":"24","author":"Ciurea","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.bulcan.2019.07.011_bib0420","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/ajh.24963","article-title":"Donor age determines outcome in acute leukemia patients over 40\u00a0undergoing haploidentical hematopoietic cell transplantation","volume":"93","author":"Canaani","year":"2018","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.bulcan.2019.07.011_bib0425","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1182\/blood-2014-03-563130","article-title":"Who is the best donor for a related HLA haplotype-mismatched transplant?","volume":"124","author":"Wang","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2019.07.011_bib0430","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-016-0265-2","article-title":"How do we choose the best donor for T-cell-replete. HLA-haploidentical transplantation?","volume":"9","author":"Chang","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"26","key":"10.1016\/j.bulcan.2019.07.011_bib0435","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.bulcan.2019.07.011_bib0440","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41409-017-0016-1","article-title":"Comparable survival using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMT","volume":"53","author":"Cesaro","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.bulcan.2019.07.011_bib0445","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bbmt.2017.10.002","article-title":"Impact of HLA disparity in haploidentical bone marrow transplantation followed by high-dose cyclophosphamide","volume":"24","author":"Raiola","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.bulcan.2019.07.011_bib0450","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1182\/bloodadvances.2017006429","article-title":"The impact of HLA matching on outcomes of unmanipulated haploidentical HSCT is modulated by GVHD prophylaxis","volume":"1","author":"Lorentino","year":"2017","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.bulcan.2019.07.011_bib0455","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1182\/bloodadvances.2018018291","article-title":"Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch?","volume":"2","author":"Robinson","year":"2018","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.bulcan.2019.07.011_bib0460","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41409-017-0072-6","article-title":"Impact of HLA allele mismatch at HLA-A, -B, -C, -DRB1, and -DQB1\u00a0on outcomes in haploidentical stem cell transplantation","volume":"53","author":"Huo","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.bulcan.2019.07.011_bib0465","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1016\/j.bbmt.2018.06.004","article-title":"Early fever after haploidentical bone marrow transplantation correlates with class II HLA-mismatching and myeloablation but not outcomes","volume":"24","author":"McCurdy","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.bulcan.2019.07.011_bib0470","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1159\/000323935","article-title":"Role of natural killer cells in hematopoietic stem cell transplantation: myth or reality?","volume":"3","author":"Nguyen","year":"2011","journal-title":"J Innate Immun"},{"key":"10.1016\/j.bulcan.2019.07.011_bib0475","doi-asserted-by":"crossref","DOI":"10.1038\/s41409-018-0332-0","article-title":"The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation","author":"Ciurea","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"3","key":"10.1016\/j.bulcan.2019.07.011_bib0480","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.bbmt.2017.11.042","volume":"24","author":"Wanquet","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.bulcan.2019.07.011_bib0485","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.bbmt.2009.11.022","article-title":"Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative. HLA-haploidentical bone marrow transplantation","volume":"16","author":"Symons","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"10.1016\/j.bulcan.2019.07.011_bib0490","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/ejh.12616","article-title":"Inhibitory killer cell immunoglobulin-like receptor (iKIR) mismatches improve survival after T-cell-repleted haploidentical transplantation","volume":"96","author":"Bastos-Oreiro","year":"2016","journal-title":"Eur J Haematol"},{"issue":"2","key":"10.1016\/j.bulcan.2019.07.011_bib0495","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1182\/blood-2017-05-780668","article-title":"NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications","volume":"131","author":"Russo","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.bulcan.2019.07.011_bib0500","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/s41375-018-0170-5","article-title":"Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide","volume":"33","author":"Shimoni","year":"2019","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.bulcan.2019.07.011_bib0505","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.transproceed.2017.09.070","article-title":"Donor selection based on Killer Cell Immunoglobulin-Like Receptor (KIR) genotype may improve outcome after T-Cell-Replete haploidentical transplantation","volume":"50","author":"Tor\u00edo","year":"2018","journal-title":"Transplant Proc"},{"issue":"12","key":"10.1016\/j.bulcan.2019.07.011_bib0510","doi-asserted-by":"crossref","first-page":"e1242546","DOI":"10.1080\/2162402X.2016.1242546","volume":"5","author":"Wang","year":"2016","journal-title":"Oncoimmunology"},{"issue":"5","key":"10.1016\/j.bulcan.2019.07.011_bib0515","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.bbmt.2014.02.001","article-title":"Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide","volume":"20","author":"Castagna","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.bulcan.2019.07.011_bib0520","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/bjh.13923","article-title":"Low incidence of chronic GVHD after HLA-haploidentical peripheral blood stem cell transplantation with post-transplantation cyclophosphamide in older patients","volume":"176","author":"Devillier","year":"2017","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.bulcan.2019.07.011_bib0525","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1038\/s41409-018-0183-8","article-title":"CD3+ graft cell count influence on chronic GVHD in haploidentical allogeneic transplantation using post-transplant cyclophosphamide","volume":"53","author":"Mussetti","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"26","key":"10.1016\/j.bulcan.2019.07.011_bib0530","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1200\/JCO.2017.72.8428","article-title":"Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-Cell-Replete haploidentical donor transplantation using post-transplant cyclophosphamide","volume":"35","author":"Bashey","year":"2017","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.bulcan.2019.07.011_bib0535","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/cncr.31228","article-title":"Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide","volume":"124","author":"Ruggeri","year":"2018","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.bulcan.2019.07.011_bib0540","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1182\/blood-2011-03-344853","article-title":"Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2\u00a0trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts","volume":"118","author":"Brunstein","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bulcan.2019.07.011_bib0545","doi-asserted-by":"crossref","first-page":"e563","DOI":"10.1038\/bcj.2017.44","article-title":"Survival, toxicity and length of stay after haploidentical or cord blood transplantation in a Latin American center: a cross-sectional, comparative study","volume":"7","author":"Esteves","year":"2017","journal-title":"Blood Cancer J"},{"issue":"9","key":"10.1016\/j.bulcan.2019.07.011_bib0550","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1038\/leu.2015.98","article-title":"Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia","volume":"29","author":"Ruggeri","year":"2015","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.bulcan.2019.07.011_bib0555","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/cncr.29271","article-title":"Unrelated cord blood compared with haploidentical grafts in patients with hematological malignancies","volume":"121","author":"El-Cheikh","year":"2015","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.bulcan.2019.07.011_bib0560","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1053\/j.seminhematol.2016.01.007","article-title":"Cord blood versus haploidentical stem cell transplantation for hematological malignancies","volume":"53","author":"Kekre","year":"2016","journal-title":"Semin Hematol"},{"issue":"8","key":"10.1016\/j.bulcan.2019.07.011_bib0565","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1182\/blood-2015-04-639831","article-title":"Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia","volume":"126","author":"Ciurea","year":"2015","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.bulcan.2019.07.011_bib0570","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3324\/haematol.2018.189258","volume":"103","author":"Salvatore","year":"2018","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.bulcan.2019.07.011_bib0575","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/j.bbmt.2015.03.003","article-title":"Total body irradiation-based myeloablative haploidentical stem cell transplantation is a safe and effective alternative to unrelated donor transplantation in patients without matched sibling donors","volume":"21","author":"Solomon","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"10.1016\/j.bulcan.2019.07.011_bib0580","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.bbmt.2014.05.029","article-title":"Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts","volume":"20","author":"Raiola","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.bulcan.2019.07.011_bib0585","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bbmt.2015.08.029","volume":"22","author":"Blaise","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.bulcan.2019.07.011_bib0590","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.bbmt.2018.02.002","article-title":"HLA-Matched sibling versus unrelated versus haploidentical related donor allogeneic hematopoietic stem cell transplantation for patients aged over 60\u00a0years with acute myeloid leukemia: a single-center donor comparison","volume":"24","author":"Devillier","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.bulcan.2019.07.011_bib0595","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/s41409-018-0387-y","article-title":"Post-transplantation cyclophosphamide-based haploidentical versus Atg-based unrelated donor allogeneic stem cell transplantation for patients younger than 60\u00a0years with hematological malignancies: a single-center experience of 209\u00a0patients","volume":"54","author":"Pagliardini","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.bulcan.2019.07.011_bib0600","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.bbmt.2017.01.068","article-title":"T Cell-Replete peripheral blood haploidentical hematopoietic cell transplantation with post-transplantation cyclophosphamide results in outcomes similar to transplantation from traditionally matched donors in active disease acute myeloid leukemia","volume":"23","author":"How","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.bulcan.2019.07.011_bib0605","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1182\/blood.V99.3.806","volume":"99","author":"Drobyski","year":"2002","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.bulcan.2019.07.011_bib0610","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1002\/cncr.30180","article-title":"Results of a 2-arm, phase 2\u00a0clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation","volume":"122","author":"Gaballa","year":"2016","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.bulcan.2019.07.011_bib0615","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/ejh.13030","article-title":"Risk-adapted GVHD prophylaxis with post-transplantation cyclophosphamide in adults after related, unrelated, and haploidentical transplantations","volume":"100","author":"Moiseev","year":"2018","journal-title":"Eur J Haematol"},{"issue":"30","key":"10.1016\/j.bulcan.2019.07.011_bib0620","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1200\/JCO.2017.72.6869","volume":"35","author":"Mart\u00ednez","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.bulcan.2019.07.011_bib0625","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.bbmt.2017.11.030","volume":"24","author":"Mariotti","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"26","key":"10.1016\/j.bulcan.2019.07.011_bib0630","doi-asserted-by":"crossref","first-page":"3450","DOI":"10.1182\/blood-2016-01-694349","article-title":"Single- vs double-unit cord blood transplantation for children and young adults with acute leukemia or myelodysplastic syndrome","volume":"127","author":"Michel","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bulcan.2019.07.011_bib0635","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.bbmt.2015.01.020","article-title":"Single-agent high-dose cyclophosphamide for graft-versus-host disease prophylaxis in human leukocyte antigen-matched reduced-intensity peripheral blood stem cell transplantation results in an unacceptably high rate of severe acute graft-versus-host disease","volume":"21","author":"Bradstock","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.bulcan.2019.07.011_bib0320","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/bmt.2016.215","article-title":"Comparable outcomes with marrow or peripheral blood as stem cell sources for hematopoietic cell transplantation from haploidentical donors after non-ablative conditioning: a matched-pair analysis","volume":"51","author":"O\u2019Donnell","year":"2016","journal-title":"Bone Marrow Transplant"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455119303029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455119303029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:31:52Z","timestamp":1757791912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455119303029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":64,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0007455119303029"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2019.07.011","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Greffe de cellules souches h\u00e9matopo\u00ef\u00e9tiques haplo-identiques avec cyclophosphamide en post-greffe\u00a0: comment choisir le meilleur donneur en 2019\u00a0? Recommandations de la Soci\u00e9t\u00e9 francophone de greffe de m\u0153lle et de th\u00e9rapie cellulaire (SFGM-TC)","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2019.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer.","name":"copyright","label":"Copyright"}]}}